Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison.
Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison.
复制标题
DOI：
10.1038/s41416-018-0215-6
复制
发表时间：
2018-08
影响因子：
8.8
通讯作者：
Bastiaannet E
中科院分区：
文献类型：
--
作者：
Claassen YHM;Vermeer NCA;Iversen LH;van Eycken E;Guren MG;Mroczkowski P;Martling A;Codina Cazador A;Johansson R;Vandendael T;Wibe A;Moller B;Lippert H;Rutten HJT;Portielje JEA;Liefers GJ;Holman FA;van de Velde CJH;Bastiaannet E
老年直肠癌患者的最佳治疗策略仍不清楚。本研究旨在比较80岁以上直肠癌患者的治疗和生存情况。纳入2001年至2010年间≥80岁诊断为直肠癌的患者。来自比利时(BE)、丹麦(DK)、荷兰(NL)、挪威(NO)和瑞典(SE)的基于人口的队列在治疗策略和5年相对存活率(RS)方面与邻国进行了并列比较，并根据性别和年龄进行了调整。分析分别针对I-III期患者和IV期患者进行。总体而言，19名 634名直肠癌患者纳入其中。对于I-III期患者，5年RS从BE的61.7%到SE的72.3%不等。术前放疗比例NO组为7.9%，SE组为28.9%。对于IV期患者，5年RS从NL的2.8%到BE的5.6%不等。DK组的手术率为22.2%，NO组为40.8%。对于80岁以上的直肠癌患者，欧洲国家之间的5年相对生存率有很大的差异，其次是治疗上的巨大差异，特别是在I-III期患者术前放射治疗的使用方面，以及在IV期患者接受手术的比率方面。
The optimal treatment strategy for older rectal cancer patients remains unclear. The current study aimed to compare treatment and survival of rectal cancer patients aged 80+. Patients of ≥80 years diagnosed with rectal cancer between 2001 and 2010 were included. Population-based cohorts from Belgium (BE), Denmark (DK), the Netherlands (NL), Norway (NO) and Sweden (SE) were compared side by side for neighbouring countries on treatment strategy and 5-year relative survival (RS), adjusted for sex and age. Analyses were performed separately for stage I–III patients and stage IV patients. Overall, 19 634 rectal cancer patients were included. For stage I–III patients, 5-year RS varied from 61.7% in BE to 72.3% in SE. Proportion of preoperative radiotherapy ranged between 7.9% in NO and 28.9% in SE. For stage IV patients, 5-year RS differed from 2.8% in NL to 5.6% in BE. Rate of patients undergoing surgery varied from 22.2% in DK to 40.8% in NO. Substantial variation was observed in the 5-year relative survival between European countries for rectal cancer patients aged 80+, next to a wide variation in treatment, especially in the use of preoperative radiotherapy in stage I–III patients and in the rate of patients undergoing surgery in stage IV patients.
登录
查看更多内容
影响因子：
51.1
作者：
Erlandsson, Johan;Holm, Torbjorn;Martling, Anna
通讯作者：
Martling, Anna
影响因子：
3.1
作者：
Guren, Marianne G.;Korner, Hartwig;Wibe, Arne
通讯作者：
Wibe, Arne
影响因子：
158.5
作者：
Sauer, R;Becker, H;Raab, R
通讯作者：
Raab, R
影响因子：
3
作者：
Bradley, Cathy J.;Yabroff, K. Robin;Lamont, Elizabeth B.
通讯作者：
Lamont, Elizabeth B.
影响因子：
8.4
作者：
Martijn, H.;Vulto, J. C. M.
通讯作者：
Vulto, J. C. M.